Sunoptic Technologies has acquired LuxteL
Sunoptic Technologies has acquired LuxteL for an undisclosed consideration.
Sunoptic Technologies® OEM Business is focused in four major market segments: medical technology, life science, industrial/machine vision, and dental for product development and manufacturing of fiberoptic and illumination applications. Sunoptics Surgical® provides surgical headlights, Xenon and LED light sources, video cameras, documentation/recording devices, fiber optic cables and other related products. The company was founded 35 years ago and is based in Jacksonville, Florida.
LuxteL's focus in the specialty lighting industry is on a family of ceramic xenon short arc lamps, trademarked CeraLux. These products are more rugged, offer better color rendition and eliminate environmental concerns associated with other lighting techniques.
Oaklins' team in Jacksonville advised the buyer in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more